Related Experiment Videos
[Muscle biopsy studies in malignant hyperthermia].
Anasthesie, Intensivtherapie, Notfallmedizin
|February 1, 1983
Summary
Malignant hyperthermia patients often show subclinical myopathy on muscle biopsy. Identifying these carriers is crucial for preventing severe reactions, though diagnosis can be challenging.
Area of Science:
- Neurology
- Genetics
- Pathology
Background:
- Malignant hyperthermia (MH) is a severe pharmacogenetic disorder triggered by anesthetic agents.
- Individuals at risk for MH may harbor underlying myopathies that are not clinically apparent.
Observation:
- Muscle biopsies were performed on 41 patients with suspected malignant hyperthermia and their relatives.
- Significant myopathic alterations, including minimal changes and syndrome-like tissue alterations (e.g., core disease, muscle dystrophy), were observed in 46.3% of patients.
- No changes or only acute rhabdomyolysis were detected in the remaining patients.
Findings:
- The study confirms the presence of a morphologically detectable "subclinical myopathy" in approximately half of the investigated patients.
- Significant variability in the presentation and spectrum of these myopathies was noted, even within families.
- Morphological changes are often absent in children, suggesting potential underdiagnosis in younger populations.
Implications:
- Subclinical myopathies associated with malignant hyperthermia may be more prevalent than previously assumed.
- Accurate diagnosis is challenging, with pharmacological fiber contraction tests being the most reliable method.
- Screening through patient history and creatine phosphokinase (CPK) levels can aid in identifying at-risk individuals, especially those with paroxysmal myoglobinuria.